Janssen’s cancer drug, Darzalex, should receive interim funding by the Cancer Drugs Fund (CDF), U.K.’s National Institute for Health and Care Excellence (NICE) announced.
The agency in a guidance published in March 2017 had originally rejected the drug.
NICE, according to a pharmaphorum report, said uncertainties remain with some of the data regarding Darzalex, and that the CDF should fund the drug through November 2020 to allow further research.
The agency said after the funding expires, it could review the 2017 guidance with the new information.
“Janssen has an inherent commitment to providing innovative and life-extending treatments to patients, therefore we are delighted to be able to provide an extra line of therapy to patients and doctors across the U.K.,” Janssen-Cilag Health Economics, Market Access and Reimbursement and Advocacy Director Jennifer Lee said.